MedTrace Logo

Adjuvant Effect of Chloroquine on Gemcitabine

NCT01777477 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety by defining the maximum tolerated dose (MTD) of Choloroquine when combined with Gemcitabine, and to evaluate preliminary efficacy of combined systemic Gemcitabine and Chloroquine. In addition, the influence of the treatment on the anti-cancer immunity and the value of GOLPH2 as serum marker for pancreatic cancer will be assessed within a translational objective.

* Trial with medicinal product

Conditions

Interventions

DRUG

Chloroquine

Addition of Chloroquine to Gemcitabine

DRUG

Gemcitabine

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Panagiotis Samaras, MD · University Hospital Zurich, Department of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777477 on ClinicalTrials.gov